TiGenix’s Cx601 trial shows positive results
The ADMIRE-CD trial, which was double-blind and placebo-controlled, focused on patients suffering from Crohn’s disease with complex perianal fistulas who had insufficient responses to prior therapies, including anti-TNFs. The study, which lasted one year, established that Cx601 is safe and tolerable among patients.
The trial included 212 random patients from seven different European countries and Israel. All patients involved in the study had previous adverse responses to at least one type of therapy that included anti-TNFs.
The primary goal of the study was combined remission by the 24th week of ADMIRE-CD. Combined remission for the trial was defined as the closing of all external openings that had received treatment, which would be confirmed by an MRI. This goal was also examined at the completion of the trial in week 52.
Organizations in this story
TiGenix NV Leuven, Flanders